DUBLIN, September 15, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way" report to their offering.
The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably from $28.1 billion in 2015 to $46.6 billion by 2022, at a compound annual growth rate (CAGR) of 7.5%.
Our latest report states that although the patent expirations of the commercially successful Advair, Symbicort, Ventolin and Spiriva will allow generics to enter the market, the impact of these expirations will be offset by the approval of new products.
One of the publishers analysts states that: Recently approved products in COPD include multiple long-acting beta-2 agonist/long-acting muscarinic antagonist (LAMA) fixed-dose combinations, some of which are forecast to generate over $1 billion by 2022, and include GlaxoSmithKline's (GSK's) Anoro, Novartis's Ultibro and Boehringer Ingelheim's Stiolto.
The approvals of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab) and Cinqair (reslizumab), marketed by GSK and Novartis, respectively, are also forecast to have a strong commercial impact on the market.
Although GSK is currently the leading company in terms of revenue generated from respiratory disorder products, GBI Research expects Vertex, which specialises in the cystic fibrosis segment, to overtake GSK by 2022.
Key Topics Covered:
1 Tables & Figures
3 Key Marketed Products
3.2 Advair - GSK
3.3 Spiriva - Boehringer Ingelheim, Pfizer
3.4 Symbicort - AstraZeneca/Astellas
3.5 Singulair (montelukast) - Merck & Co.
3.6 Flixotide/Flovent - GSK
3.7 Ventolin - GSK
3.8 Kalydeco - Vertex
3.9 Pulmozyme - Roche
3.10 Esbriet - Roche
3.11 TOBI - Novartis
4 Pipeline Landscape Assessment
5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.4 Assessment of Key Pipeline Products
5.4.1 Dupilumab - Regeneron Pharmaceuticals/Sanofi
5.4.2 Benralizumab - AstraZeneca/Medimmune
5.4.3 Lebrikizumab - Roche/Genentech
5.4.4 PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrronium) - AstraZeneca/Pearl Therapeutics
5.4.5 Tralokinumab - AstraZeneca
5.4.6 Batefenterol - GSK/Theravance
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.6 Boehringer Ingelheim
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.2 Co-development Deals
For more information about this report visit http://www.researchandmarkets.com/research/fmz5wv/global
Related Topics: Respiratory Drugs, Endocrine and Metabolic Disorder Drugs, Asthma Drugs
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-respiratory-drugs-market-to-2022---gsk-is-currently-the-market-leader-of-the-28-billion-market---research-and-markets-300328696.html
SOURCE Research and Markets